Self-assembling colloidal system for the ocular administration of cyclosporine A

Cornea

Volumn 33, Issue 1, 2014, Pages 77-81

  Luschmann, Christoph ^a   Tessmar, Joerg ^b   Schoeberl, Simon ^c   Strau, Olaf ^c,d   Luschmann, Karl ^e   Goepferich, Achim ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b UNIVERSITY OF WÜRZBURG   (Germany)

^c UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^e Pharma Stulln GmbH   (Germany)

Author keywords

bioavailability; cyclosporin A; dry eye disease; poor solubility; surfactant micelles

Indexed keywords

CYCLOSPORIN A; CYCLOSPORIN D; FATTY ALCOHOL ETHER; MACROGOL; NONIONIC SURFACTANT; OLIVE OIL; UNCLASSIFIED DRUG; COLLOID; CYCLOSPORIN; DRUG CARRIER; EYE DROPS; IMMUNOSUPPRESSIVE AGENT; MICELLE; SURFACTANT;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AQUEOUS SOLUTION; ARTICLE; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG UPTAKE; ENCAPSULATION; KERATITIS; MICELLE; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; SELF ASSEMBLING COLLOIDAL SYSTEM; SINGLE DRUG DOSE; SWINE; ANIMAL; ANIMAL MODEL; CHEMISTRY; COLLOID; CORNEA; INTRAOCULAR DRUG ADMINISTRATION; METABOLISM; PIG; SOLUBILITY;

ADMINISTRATION, OPHTHALMIC; ANIMALS; COLLOIDS; CORNEA; CYCLOSPORINE; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; IMMUNOSUPPRESSIVE AGENTS; MICELLES; MODELS, ANIMAL; OPHTHALMIC SOLUTIONS; SOLUBILITY; SURFACE-ACTIVE AGENTS; SWINE;

EID: 84890425770     PISSN: 02773740     EISSN: 15364798     Source Type: Journal    
DOI: 10.1097/ICO.0b013e3182a7f3bf     Document Type: Article

References (28)

1. Avunduk AM, Avunduk MC, Varnell ED, et al. The comparison of efficacies of topical corticosteroids and nonsteroidal anti-inflammatory drops on dry eye patients: A clinical and immunocytochemical study. Am J Ophthalmol. 2003;136:593-602
2. Kassem MA, Abdel Rahman AA, Ghorab MM, et al. Nanosuspension as an ophthalmic delivery system for certain glucocorticoid drugs. Int J Pharm. 2007;340:126-133
3. Lee HK, Ryu IH, Seo KY, et al. Topical 0.1% prednisolone lowers nerve growth factor expression in keratoconjunctivitis sicca patients. Ophthalmology. 2006;113:198-205
4. Waldrep J, Arppe J, Jansa K, et al. High dose cyclosporin A and budesonide-liposome aerosols. Int J Pharm. 1997;152:27-36
5. Deleted in proof
6. Nussenblatt RB, Palestine AG. Cyclosporine: Immunology, pharmacology and therapeutic uses. Surv Ophthalmol. 1986;31:159-169
7. Hoffmann F, Wiederholt M. Local treatment of necrotizing scleritis with cyclosporin A. Cornea. 1985-1986;4:3-7
8. Witte A, Landgraf R, Markl A, et al. Treatment of Graves' ophthalmopathy with cyclosporin A. Klin Wochenschr. 1985;63:1000-1004
9. Lallemand F, Felt-Baeyens O, Besseghir K, et al. Cyclosporine A delivery to the eye: A pharmaceutical challenge. Eur J Pharm Biopharm. 2003;56: 307-318
10. Mithani SD, Bakatselou V, TenHoor CN, et al. Estimation of the increase in solubility of drugs as a function of bile salt concentration. Pharm Res. 1996;13:163-167
11. el Tayar N, Mark AE, Vallat P, et al. Solvent-dependent conformation and hydrogen-bonding capacity of cyclosporin A: Evidence from partition coefficients and molecular dynamics simulations. J Med Chem. 1993;36:3757-3764
12. Di Tommaso C, Bourges JL, Valamanesh F, et al. Novel micelle carriers for cyclosporin A topical ocular delivery: In vivo cornea penetration, ocular distribution and efficacy studies. Eur J Pharm Biopharm. 2012; 81:257-264
13. Kuwano M, Ibuki H, Morikawa N, et al. Cyclosporine A formulation affects its ocular distribution in rabbits. Pharm Res. 2002;19:108-111
14. Milani JK, Pleyer U, Dukes A, et al. Prolongation of corneal allograft survival with liposome-encapsulated cyclosporine in the rat eye. Ophthalmology. 1993;100:890-896
15. Calvo P, Sanchez A, Martinez J, et al. Polyester nanocapsules as new topical ocular delivery systems for cyclosporin A. Pharm Res. 1996;13:311-315
16. Kaswan RL. Intraocular penetration of topically applied cyclosporine. Transplant Proc. 1988;20:650-655
17. Le Bourlais CA, Chevanne F, Turlin B, et al. Effect of cyclosporine A formulations on bovine corneal absorption: Ex-vivo study. J Microencapsul. 1997;14:457-467
18. Di Tommaso C, Behar-Cohen F, Gurny R, et al. Colloidal systems for the delivery of cyclosporin A to the anterior segment of the eye. Ann Pharm Fr. 2011;69:116-123
19. BenEzra D, Maftzir G. Ocular penetration of cyclosporin A. The rabbit eye. Invest Ophthalmol Vis Sci. 1990;31:1362-1366
20. Holland EJ, Olsen TW, Ketcham JM, et al. Topical cyclosporin A in the treatment of anterior segment inflammatory disease. Cornea. 1993;12: 413-419
21. Di Tommaso C, Valamanesh F, Miller F, et al. A novel cyclosporin a aqueous formulation for dry eye treatment: In vitro and in vivo evaluation. Invest Ophthalmol Vis Sci. 2012;53:2292-2299
22. Luschmann C, Tessmar J, Schoeberl S, et al. Developing an in situ nanosuspension: A novel approach towards the efficient administration of poorly soluble drugs at the anterior eye, Eur J Pharm Sci. 2013;50:385-392
23. Restasis (cyclosporine ophthalmic emulsion) 0.05% [package insert]. Irvine, CA: Allergan, Inc; 2010
24. Elsabahy M, Perron ME, Bertrand N, et al. Solubilization of docetaxel in poly(ethylene oxide)-block-poly(butylene/styrene oxide) micelles. Biomacromolecules. 2007;8:2250-2257
25. Mondon K, Zeisser-Labouèbe M, Gurny R, et al. Novel cyclosporin A formulations using MPEG-hexyl-substituted polylactide micelles: A suitability study. Eur J Pharm Biopharm. 2011;77:56-65
26. Daull P, Lallemand F, Philips B, et al. Distribution of cyclosporine A in ocular tissues after topical administration of cyclosporine A cationic emulsions to pigmented rabbits. Cornea. 2013;32:345-354
27. Yavuz B, Bozdaǧ Pehlivan S, Unlü N. An overview on dry eye treatment: Approaches for cyclosporin a delivery. Scientific World Journal. 2012;2012:194848
28. Di Tommaso C, Torriglia A, Furrer P, et al. Ocular biocompatibility of novel cyclosporin A formulations based on methoxy poly(ethylene glycol)-hexylsubstituted poly(lactide) micelle carriers. Int J Pharm. 2011;416:515-524